750 TWT-101: a first-in-clinic, phase 1/2 study of CFI-402411, a hematopoietic progenitor kinase-1 (HPK1) inhibitor, as a single agent and in combination with pembrolizumab in subjects with advanced solid malignancies

彭布罗利珠单抗 医学 内科学 胃肠病学 肿瘤科 癌症 免疫疗法
作者
Kyriakos Papadopoulos,Siqing Fu,Erika Hamilton,Alexander I. Spira,Scott A. Laurie,Judy Wang,Brigette Ma,Anna Spreafico,Manish Sharma,Quincy Chu,Mark Bray,Glenn Michelson,Dih-Yih Chen,Linh Nguyen,Emily Roberts-Thomson,Omid Hamid
标识
DOI:10.1136/jitc-2022-sitc2022.0750
摘要

Background

CFI-402411 is a potent inhibitor of HPK1 (Hematopoietic progenitor kinase 1), a protein serine/threonine kinase that negatively-regulates T-cell activation. Following T-cell receptor engagement, HPK1 phosphorylates SLP-76, to down-regulate signals required for T-cell activation and proliferation1,2. CFI-402411 is expected to relieve HPK1-mediated inhibition of T-cell activation, facilitating an anti-tumor immune response.

Methods

In this ongoing phase 1 study, part A evaluates CFI-402411 daily dose in dose escalation cohort (3+3 design) and dose expansion, part B evaluates CFI-402411 in combination with pembrolizumab in dose escalation (BOIN design) and dose expansion in pembrolizumab eligible tumors. Dose limiting toxicity (DLT) is any grade ≥3 toxicity in the first cycle of therapy (21d cycles). Starting dose was 80mg.

Results

As of 14 May 2022 (data cutoff), 25 and 9 patients (pts) enrolled to A and B respectively. Median age was 62 (30-79). Median cycles of treatment were 3 (range: 0-20). Majority of patients were male (A, 60% and B, 78%). Median prior regimens were 2 (range: A, 1-4; B, 1-3). 6pts (A, 24%) and 5pts (B, 56%) received prior anti-PD-1/anti-PD-L1 inhibitor. Diagnoses in ≥2pts for A: colorectal (6pts), pancreatic (5pts); for B: small cell lung cancer (2pts). 8 dose levels (80 to 800 mg) have been studied in A, 2 dose levels (60 and 80 mg) in B. TEAEs occurring in ≥40% of A pts: diarrhea (n=17, 68%), nausea (n=11, 44%), decreased appetite (n=10, 40%); and B: vomiting (n=4, 44%). 19pts (76%) in A and 6pts (67%) in B experienced CFI-402411 related AEs. Immune-related AEs were reported in 1pt (A; 4% [ALT and AST increase]) and 2pts (B; 22% [febrile illness, flu-like symptoms]). Grade ≥3 AEs and serious AEs occurred in 14pts (56%) and 10pts (40%) in A; and 3pts (33%) and 4pts (44%) in B. DLTs occurred in 2pts (A [800mg]: diarrhea, spinal cord compression) and 1pt (B [80mg+pembro]: flu-like symptoms). No novel toxicity signals were seen. Disease control rates were 24% in A (6/25) and 44% in B (4/9). One B patient (11%), squamous head and neck cancer (H&N) previously treated with pembrolizumab, has confirmed partial response (PR) and remains on treatment, 8 cycles. An additional H&N patient treated with monotherapy CFI-402411 achieved unconfirmed PR after data cut.

Conclusions

CFI-402411 is a well-tolerated, potent inhibitor of HPK1 with a manageable AE profile and initial evidence of activity. RP2D and additional safety and efficacy data will be reported at conference presentation.

Acknowledgements

Treadwell Therapeutics would like to thank both the patients and the research staff at enrolling centers who have helped to bring this novel therapy to the clinic.

Trial Registration

NCT04521413

References

Hu MQ. Human HPK1, a novel human hematopoietic progenitor kinase that actives the JNK/SAPK kinase cascade. Genes & Development. 1996;10:2251–2264. Lasserre RC-G. Release of serine/threonine-phosphorylated adaptors from signaling microclusters down-regulates T cell activation. Immuno Res. 2011;295:839–853.

Ethics Approval

This study obtained ethics approvals at the following ethics/IRB's; Papadopoulos, KP; Advarra IRB ID: Pro00051609 Fu, S; University of Texas MD Anderson Cancer Center Office of Human Subject Protection IRB ID 2020-0678 Hamilton, E; Advarra IRB ID: Pro00051611 Spira, A; Advarra IRB ID: Pro00043629 Laurie, S; Ontario Cancer Research Ethics Board, CTO Project ID 3320 Wang, J; Advarra IRB ID: Pro00051611 Ma, B; Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee CREC Ref. No .: 2020.367-T Spreafico, A; Ontario Cancer Research Ethics Board, CTO Project ID 3320 Sharma, M; Advarra IRB: ID Pro00051609 Chu, Q; Health Research Ethics Board of Alberta Ethics ID: HREBA.CC-20-0504_REN1 Hamid, O; WCG, IRB: IRB Tracking Number: 2020236 As evidenced by verified clinical database information all subjects gave informed consent before taking part in this clinical trial.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
华仔应助Blues汪采纳,获得10
1秒前
小小怪发布了新的文献求助10
1秒前
科研通AI2S应助Luo采纳,获得10
2秒前
2秒前
领导范儿应助kyt采纳,获得20
2秒前
fabea完成签到,获得积分10
2秒前
韶卿完成签到,获得积分10
3秒前
豆豆欢欢乐完成签到 ,获得积分10
3秒前
3秒前
Lorde完成签到,获得积分10
4秒前
zh发布了新的文献求助10
5秒前
量子星尘发布了新的文献求助10
5秒前
科目三应助肉肉采纳,获得10
6秒前
哄不好的南完成签到 ,获得积分10
6秒前
7秒前
CodeCraft应助勤奋的丸子采纳,获得10
7秒前
ananas完成签到,获得积分20
8秒前
聪慧的草丛完成签到 ,获得积分10
8秒前
8秒前
9秒前
9秒前
打打应助稳重傲柔采纳,获得10
9秒前
10秒前
大方安白发布了新的文献求助10
10秒前
11秒前
neimy发布了新的文献求助30
11秒前
KhalilHao完成签到,获得积分10
12秒前
12秒前
兴奋赛君发布了新的文献求助10
12秒前
平淡如南发布了新的文献求助10
12秒前
12秒前
司空晓山发布了新的文献求助30
13秒前
j_lan发布了新的文献求助10
14秒前
科目三应助handsomelin采纳,获得10
14秒前
aa发布了新的文献求助10
14秒前
sujustin333发布了新的文献求助10
15秒前
平常的狗完成签到,获得积分10
15秒前
坦率的可仁完成签到,获得积分10
15秒前
丘比特应助zh采纳,获得10
16秒前
17秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969458
求助须知:如何正确求助?哪些是违规求助? 3514286
关于积分的说明 11173363
捐赠科研通 3249652
什么是DOI,文献DOI怎么找? 1794948
邀请新用户注册赠送积分活动 875501
科研通“疑难数据库(出版商)”最低求助积分说明 804836